According to Bioject, the new Zetajet system is the latest advance in needle-free delivery systems, offering a significant array of unique product features and patient benefits that can provide highly competitive differentiation to a wide variety of injectables market segments.
The Zetajet needle-free injection therapy system is a compact, spring-powered, needle-free injection device. It is intended to deliver vaccines and injectable medications either subcutaneously or intramuscularly. The Zetajet uses jet force to propel a finely dispersed stream of injectable medication into the subcutaneous or intramuscular tissue without the use of a needle, the company said.
Ralph Makar, president and CEO of Bioject, said: “With the FDA 510(k) clearance achieved, we are now determined to find the best strategic partners with whom to introduce the Zetajet, in combination with the right therapeutics, in order to create highly differentiated products that maximally enhance the patient experience.”